SGS continues to invest in bioanalytical testing to increase efficiency and regulatory compliance at its Poitiers, France, laboratory

The investment will enable higher throughput of samples, and electronic data capture to ensure integrity of information in regulatory submission and acceptances.

The investment in the IRM is the latest strategic step for the company in its key business area of large molecule bioanalysis. The module allows for faster immunogenicity data processing and easier consolidation of sample data, increasing the efficiency in terms of time and cost for clients. The integration of the module into the existing LIMS infrastructure means bioanalytical studies can be managed by one single tool, and clients’ immunogenicity data can be stored and processed within a secure environment.

The new module has been fully validated by SGS and can be used for GCP and GLP compliant studies.

“For our clients, this investment will reduce the time spent processing complex, bioanalytical data, and also ensure that any regulatory submission based upon results and data generated by SGS will stand up to scrutiny,” commented Alain Renoux, Laboratory Director of SGS Life Sciences Poitiers. “As a company, we are seeing much greater demand for bioanalytical testing as this field of research widens, and SGS continues to invest in areas that benefit our clients’ long term goals.”

With 20 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms. In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.